Dr. Fuchs on Angiogenesis in Gastric Cancer

Charles S. Fuchs, MD, MPH
Published Online: Thursday, February 20, 2014
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting angiogenesis in the treatment of gastric cancer.

In the AVAGAST trial, patients were randomized to chemotherapy or chemotherapy plus bevacizumab in the frontline. Results from the trial indicated a benefit to progression-free survival (PFS) and response, but no significant effect on overall survival (OS).

Fuchs says he was involved in a randomized study of ramucirumab, a monoclonal antibody against VEGFR2, compared with placebo in the second-line. Treatment with ramucirumab demonstrated significant improvement to OS and PFS, as well as a trivial toxicity profile.

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
$auto_registration$